Ridogrel does not increase the speed and rate of coronary recanalization in patients with myocardial infarction treated with alteplase and heparin.

No abstract is available for this paper.

• Publication year

  1994

• Venue

  European Heart Journal

• Publication date

  1994-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/OXFORDJOURNALS.EURHEARTJ.A060564PMID 8056007
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Endogenous prostaglandin endoperoxides may alter infarct size in the presence of thromboxane synthase inhibition: studies in a rabbit model of coronary artery occlusion-reperfusion.

  1993cited by this paper
• Combined ADP and Thromboxane A2 Antagonism Prevents Cyclic Flow Variations in Stenosed and Endothelium‐Injured Arteries in Nonhuman Primates

  1993cited by this paper
• Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.

  1992cited by this paper
• Differential effects of thromboxane A2 synthase inhibition, singly or combined with thromboxane A2/prostaglandin endoperoxide receptor antagonism, on occlusive thrombosis elicited by endothelial cell injury or by deep vascular damage in canine coronary arteries.

  1991cited by this paper
• The effect of atherosclerosis on the vasomotor response of coronary arteries to mental stress.

  1991cited by this paper
• Thromboxane A2/prostaglandin endoperoxide (TXA2/PG‐END) receptor binding properties in human platelets of ridogrel, a combined TXA2 synthase inhibitor—TXA2/PG‐END receptor antagonist

  1991cited by this paper
• Combined thromboxane A2 synthetase inhibition and receptor blockade are effective in preventing spontaneous and epinephrine-induced canine coronary cyclic flow variations.

  1990cited by this paper
• R68070, a combined thromboxane/endoperoxide receptor antagonist and thromboxane synthase inhibitor, inhibits human platelet activation in vitro and in vivo: a comparison with aspirin.

  1990cited by this paper
• Responses of angiographically normal human coronary arteries to intracoronary injection of acetylcholine by age and segment. Possible role of early coronary atherosclerosis.

  1990cited by this paper
• Ridogrel, a Combined Thromboxane Synthase Inhibitor and Receptor Blocker, Decreases Elevated Plasma β-Thromboglobulin Levels in Patients with Documented Peripheral Arterial Disease

  1990cited by this paper
• Endogenous prostaglandin endoperoxides and prostacyclin modulate the thrombolytic activity of tissue plasminogen activator. Effects of simultaneous inhibition of thromboxane A2 synthase and blockade of thromboxane A2/prostaglandin H2 receptors in a canine model of coronary thrombosis.

  1990cited by this paper
• Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease.

  1990cited by this paper
• R 68 070: Thromboxane A2 Synthetase Inhibition and Thromboxane A2/Prostaglandin Endoperoxide Receptor Blockade Combined in One Molecule - I. Biochemical Profile In Vitro

  1989cited by this paper
• R 68 070: Thromboxane A2 Synthetase Inhibition and Thromboxane A2/Prostaglandin Endoperoxide Receptor Blockade Combined in One Molecule - II. Pharmacological Effects In Vivo and Ex Vivo

  1989cited by this paper
• Mediation of reocclusion by thromboxane A2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis.

  1988cited by this paper
• Responses of coronary arteries of cardiac transplant patients to acetylcholine.

  1988cited by this paper
• Prostaglandin endoperoxides modulate the response to thromboxane synthase inhibition during coronary thrombosis.

  1988cited by this paper
• Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge.

  1987cited by this paper
• Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism.

  1987cited by this paper
• Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries.

  1986cited by this paper
• Thromboxane synthase inhibition potentiates washed platelet activation by endogenous and exogenous arachidonic acid.

  1985cited by this paper
• Double-blind randomised trial of intravenous tissue-type plasminogen activator versus placebo in acute myocardial infarction.

  1985cited by this paper
• Inhibition of thromboxane synthetase does not necessarily prevent platelet aggregation.

  1981cited by this paper
• Role of blood platelets and prostaglandins in coronary artery disease.

  1981cited by this paper
• Endogenous prostacyclin contributes to the efficacy of a thromboxane synthetase inhibitor for preventing coronary artery thrombosis.

  1981cited by this paper

• Antiplatelet Drugs — Do We Need New Options?

  2010cites this paper
• This material is the copyright of the original publisher. Unauthorised copying and distribution is prohibited. Antiplatelet Drugs - Do We Need New Options? With a Reappraisal of Direct Thromboxane Inhibitors

  2010cites this paper
• Acute ST-segment elevation myocardial infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

  2008cites this paper
• Advances in antiplatelet therapy

  2003cites this paper
• Stroke: antithrombin versus antiplatelet therapy

  2000cites this paper
• Advances in antithrombotic therapy of acute myocardial infarction.

  1999cites this paper
• [Optimization of thrombolytic treatment in acute myocardial infarct: the role of new fibrinoselective drugs and their combination with new antithrombotics].

  1998cites this paper
• Optimización del tratamiento trombolítico en el infarto agudo de miocardio: papel de los nuevos fármacos fibrinoselectivos y de la asociación con los nuevos antitrombóticos

  1998cites this paper
• Effects of inhibition of sarcoplasmic reticulum calcium uptake on contraction in myocytes isolated from failing human ventricle.

  1997cites this paper
• New antiplatelet drugs.

  1997cites this paper
• Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators.

  1997cites this paper